For Immediate Release:
March 14, 2019
Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org
The studies will be funded through a collaboration between the NCCN Oncology Research Program and Taiho Oncology, Inc. to investigate the effectiveness of trifluridine and tipiracil.
PLYMOUTH MEETING, PA [March 14, 2019] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has funded three investigators from NCCN Member Institutions through a collaborative scientific research relationship with Taiho Oncology, Inc. to further evaluate the clinical effectiveness and safety of trifluridine and tipiracil (TAS-102) for treatment of various advanced, solid tumors.
The following studies were awarded funding through NCCN ORP:
- Patrick Boland, MD, Roswell Park Comprehensive Cancer Center, A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO)
- Amit Mahipal, MBBS, Mayo Clinic Cancer Center, Phase II Trial of trifluridine/tipiracil in Combination with Irinotecan in Biliary Tract Cancers
- Sarbajit Mukherjee, MD, MS, Roswell Park Comprehensive Cancer Center, Use of Trifluridine/tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal junction (GEJ) Adenocarcinoma
“NCCN ORP congratulates Drs. Boland, Mahipal, and Mukherjee on their awards,” said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. “We look forward to working with them to learn more about how patients with different cancers respond to this treatment, particularly in combination with other agents. We hope this research will lead to a better understanding of how to improve outcomes for people with colorectal, biliary tract, esophageal, and other cancers.”
“Taiho Oncology is excited to collaborate with the NCCN ORP to further the investigation of trifluridine/tipiracil in metastatic cancer,” said Martin Birkhofer, MD, Senior Vice President and Chief Medical Officer, Taiho Oncology, Inc. “These awards will advance critical clinical research and reflect Taiho’s commitment to improving the lives of people with colorectal, gastric, and other advanced cancers.”
Submissions were peer reviewed by a Scientific Review Committee, which consisted of medical oncologists from NCCN Member Institutions. The funded concepts were selected based on several criteria, including scientific merit, existing data, feasibility, and the types of studies necessary to further evaluate trifluridine/tipiracil. The studies are expected to start enrolling patients in the next 10 months and be completed within two years.
The NCCN ORP draws on the expertise of the investigators at NCCN Member Institutions to facilitate all phases of clinical research in order to advance therapeutic options for people with cancer. To learn more about the NCCN ORP and ongoing clinical trials, visit NCCN.org/ORP.
# # #
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. The NCCN Member Institutions are: Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA; Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope National Medical Center, Duarte, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Rogel Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT. Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news. Follow NCCN on Twitter @NCCNnews and Facebook @National.Comprehensive.Cancer.Network.